Pompe disease management is advancing rapidly with next-generation enzyme replacement, gene therapy, and digital monitoring reshaping treatment decisions. This rare genetic disorder, caused by a deficiency in acid alpha glucosidase, leads to progressive glycogen accumulation. While infantile-onset Pompe disease presents with severe cardiomyopathy, late-onset forms typically affect skeletal and respiratory muscles. Emerging research also points to mitochondrial dysfunction and impaired autophagy as significant contributors to disease complications.
A critical challenge remains central nervous system involvement, as current enzyme replacement therapies struggle to cross the blood-brain barrier. Early identification through newborn screening, including improved sampling methods and genetic confirmation, is vital for preserving function before irreversible damage occurs.
New enzyme replacement strategies are being developed to enhance cellular uptake and improve outcomes. These include a two-component approach combining infused enzymes with oral stabilizers to boost circulating stability. Gene therapy offers a potential one-time treatment, with ongoing efforts to improve muscle targeting and reduce toxicity. Researchers are also exploring transferrin receptor-mediated delivery to enable enzyme passage across the blood-brain barrier, alongside advanced imaging to monitor treatment response.
Digital health technologies are proving instrumental in detecting subtle motor impairments, even in presymptomatic stages, paving the way for earlier interventions and more precise long-term monitoring.